Cargando…
Escitalopram Ameliorates Cardiomyopathy in Type 2 Diabetic Rats via Modulation of Receptor for Advanced Glycation End Products and Its Downstream Signaling Cascades
Type 2 diabetes mellitus (T2DM) has been recognized as a known risk factor for cardiovascular diseases. Additionally, studies have shown the prevalence of depression among people with diabetes. Thus, the current study aimed to investigate the possible beneficial effects of escitalopram, a selective...
Autores principales: | Ahmed, Lamiaa A., Shiha, Nesma A., Attia, Amina S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770111/ https://www.ncbi.nlm.nih.gov/pubmed/33384599 http://dx.doi.org/10.3389/fphar.2020.579206 |
Ejemplares similares
-
Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways
por: El-Sahar, Ayman E, et al.
Publicado: (2020) -
Soluble receptors for advanced glycation end-products prevent unilateral ureteral obstruction-induced renal fibrosis
por: Kim, Chan Ho, et al.
Publicado: (2023) -
Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
por: Alkhowaiter, Saad S., et al.
Publicado: (2023) -
Specific Inhibition of CYP4A Alleviates Myocardial Oxidative Stress and Apoptosis Induced by Advanced Glycation End-Products
por: Wang, Rui, et al.
Publicado: (2019) -
Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram
por: Chakroborty, Shreaya, et al.
Publicado: (2017)